#4: “Invokana, First in New Class of Diabetes Drugs, Approved” The effect of Invokana on CV risk was evaluated in the CANVAS (CANagliflozin cardioVascular Assessment Study) Program in >10,000 adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results